|
<HOME
August 31, 2009: Selexis and NKT Therapeutics enter into research services
agreement
Geneva, Switzerland
http://www.selexis.com/media/news_090831.html
Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today
that they have entered into a research services agreement whereby Selexis
will screen antibody variants and generate high performance CHO-based
production cell lines using their novel platform named INTEGRA-D2Mâ„¢. The
Selexis INTEGRA-D2M™ platform enables the rapid isolation of production
cell lines concomitant with the selection of lead compounds from libraries
of protein variants expressed in Chinese Hamster Ovary (CHO) cells.
Utilizing INTEGRA-D2M™, protein variant libraries of sizes larger than
103 can be screened to identify lead compounds in less than 9 weeks. The
selected CHO-based protein variant expressing clone can then be used
directly for cGMP manufacturing.
"We are excited about the partnership with NKTT, who are recognized as
leaders in the biology and therapeutic applications for modulating Natural
Killer T cells," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "Our novel and powerful INTEGRA-D2™ platform, is able to support NKTT
in rapidly making their final product decision while we also develop and
deliver a high-performance production cell line ready for cGMP
manufacturing".
"We greatly appreciate working with the team at Selexis and utilizing
their powerful technology platform" adds Dr Alem Truneh, Chief
Scientific Officer and co-founder of NKT Therapeutics.
About Selexis INTEGRA-D2M™ Platform
Developed by Selexis over the last 2 years, the Selexis INTEGRA-D2M™
platform is a simple, non-robotic based approach enabling the screening of
protein libraries in CHO cells. Such stable CHO-based libraries are
developed in less than 9 weeks and enable the rapid selection of the best
product candidates with respect to functionality (i.e. binding assay,
neutralization assay) and titers (with reduced future COGS). The platform
is also directly linked to the generation of high producing cell clones
(for cGMP manufacturing) that are then generated in 12 weeks. The benefits
of this approach are better preclinical decisions, dramatically shortened
timelines and lower overall operational costs.
About Selexis
Selexis is a privately held Swiss biotechnology company dedicated to the
development of innovative technologies and expert services that enable
significant improvements in the time, effort, and costs required to
develop and maintain high-performance mammalian cell lines used in the
expression of pharmaceutically relevant proteins (i.e. targets, MAbs,
rProteins). The company's core intellectual property portfolio is based on the
discovery and application of novel DNA based
elements that control the dynamic organization
of chromatin within all mammalian cells - Selexis
Genetic Elements™. Selexis has further developed platforms, to include:
Selexis SUREtech Vectors™, Selexis SUREfection™ Selexis SURE Cell Line
Development™
and Selexis INTEGRA-D2™.
More information
Phone: +41 (0)22 308 93 60
Email: SURE@selexis.com
About NKT Therapeutics Inc.
NKT Therapeutics, Inc. is a privately held biotechnology company focused
on developing therapeutics based on unique immune cells called natural
killer T (NKT) cells. The company's mission is to use its expertise to
develop a pipeline of first-in-class NKT-based therapeutics to treat
asthma, cancer, autoimmune and infectious diseases. For more information
on the company, please visit http://www.nktrx.com/
|